Bank of America
QNCX icon

Bank of America’s Quince Therapeutics QNCX Stock Holding History

Bank of America’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$67.1K – 6625
2025
Q4 		$67.1K Buy
100
+90
+900% +$45.3K ﹤0.01% 5744
2025
Q3 		$3.4K Sell
10
-5
-33% -$1.67K ﹤0.01% 7347
2025
Q2 		$4.79K Buy
15
+1
+7% +$229 ﹤0.01% 7300
2025
Q1 		$3.78K Sell
14
-1
-7% -$305 ﹤0.01% 7260
2024
Q4 		$5.66K Sell
15
-775
-98% -$233K ﹤0.01% 7083
2024
Q3 		$123K Hold
790
– – ﹤0.01% 6238
2024
Q2 		$118K Sell
790
-60
-7% -$10.8K ﹤0.01% 6180
2024
Q1 		$180K Hold
850
– – ﹤0.01% 5935
2023
Q4 		$179K Sell
850
-15
-2% -$3K ﹤0.01% 6122
2023
Q3 		$194K Buy
865
+50
+6% +$13.1K ﹤0.01% 5920
2023
Q2 		$245K Buy
815
+739
+972% +$230K ﹤0.01% 5707
2023
Q1 		$23.8K Buy
76
+60
+375% +$11.7K ﹤0.01% 6716
2022
Q4 		$1.98K Sell
16
-498
-97% -$83.3K ﹤0.01% 7244
2022
Q3 		$136K Sell
514
-84
-14% -$32K ﹤0.01% 6197
2022
Q2 		$265K Sell
598
-502
-46% -$355K ﹤0.01% 5896
2022
Q1 		$1.36M Sell
1,100
-22
-2% -$29.9K ﹤0.01% 4946
2021
Q4 		$2.83M Buy
1,122
+874
+352% +$5.33M ﹤0.01% 4215
2021
Q3 		$4.55M Buy
248
+163
+192% +$2.59M ﹤0.01% 3655
2021
Q2 		$903K Sell
85
-34
-29% -$285K ﹤0.01% 4991
2021
Q1 		$859K Buy
119
+74
+164% +$532K ﹤0.01% 4979
2020
Q4 		$248K Buy
45
+5
+13% +$44.3K ﹤0.01% 5469
2020
Q3 		$403K Sell
40
-2
-5% -$18.2K ﹤0.01% 4874
2020
Q2 		$384K Sell
42
-3
-7% -$27.5K ﹤0.01% 4806
2020
Q1 		$407K Buy
45
+25
+125% +$247K ﹤0.01% 4648
2019
Q4 		$224K Buy
20
+12
+150% +$72.4K ﹤0.01% 5573
2019
Q3 		$39K Sell
8
-20
-71% -$123K ﹤0.01% 6401
2019
Q2 		$239K Buy
+28
New +$167K ﹤0.01% 5533

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of America's QNCX Position: Q1 2026 in Review

Bank of America sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 100 shares — an estimated $67.1K sold.

Bank of America first reported a position in QNCX in Q2 2019 and held it in 27 quarters. The position peaked at $4.55M in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Bank of America reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 100 Quince Therapeutics shares in Q1 2026, an estimated $67.1K.
  • Bank of America first reported a position in Quince Therapeutics in Q2 2019 and held it in 27 quarters.
  • Bank of America's Quince Therapeutics position peaked at $4.55M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.